Drugs / APRATASTAT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00095342 | ? → Aug 2005 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APRATASTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL206815 ↗ |
| Known as | TMI-005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00095342 ↗ |
| Known as | TMI-05 | ChEMBL registry synonym — accepted as the source's own label CHEMBL206815 ↗ |
| Action | Inhibit | “Matrix metalloproteinase 13 inhibitor” CHEMBL206815 ↗1“ADAM17 inhibitor” CHEMBL206815 ↗ |
| Modality | Small molecule | — CHEMBL206815 ↗ |
| Route | Oral | “oral TMI-005” NCT00095342 ↗ |
| Target | ADAM17 | “ADAM17 inhibitor” CHEMBL206815 ↗ |
| Target | MMP13 | “Matrix metalloproteinase 13 inhibitor” CHEMBL206815 ↗ |